Dr. Andrew Brohl at ASCO 2023: Abstract No. 9534
2 Mga view
• 07/17/23
0
0
I-embed
administrator
Mga subscriber
At ASCO 2023, Moffitt's Dr. Andrew Brohl discusses a phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma.
Magpakita ng higit pa
Mga Komento sa Facebook
SORT BY-
Mga Nangungunang Komento
-
Pinakabagong komento